ID   OCI-My1
AC   CVCL_E338
SY   OCI-MY1; OCI-My 1; OCIMy1; OCIMY1
DR   Cosmic; 2081400
DR   Cosmic; 2367265
DR   GEO; GSM1374793
DR   Lonza; 1458
DR   Wikidata; Q54931784
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=1912582;
RX   PubMed=8138440;
RX   PubMed=10936422;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Doubling time: 24 hours (PubMed=1912582).
CC   Sequence variation: Gene deletion; HGNC; 12033; TRAF3; Zygosity=Homozygous (PubMed=17692805).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 21-03-23; Version: 16
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   PubMed=1912582; DOI=10.1182/blood.V78.8.1996.1996;
RA   Hitzler J.K., Martinez-Valdez H., Bergsagel D.E., Minden M.D.,
RA   Messner H.A.;
RT   "Role of interleukin-6 in the proliferation of human multiple myeloma
RT   cell lines OCI-My 1 to 7 established from patients with advanced stage
RT   of the disease.";
RL   Blood 78:1996-2004(1991).
//
RX   PubMed=8138440; DOI=10.1016/0360-3016(94)90107-4;
RA   Gluck S., Van Dyk J., Messner H.A.;
RT   "Radiosensitivity of human clonogenic myeloma cells and normal bone
RT   marrow precursors: effect of different dose rates and fractionation.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 28:877-882(1994).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//